Trial Profile

AST 915 in patients with essential tremor.

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Dec 2010

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AST 915 (Primary)
Indications Essential tremor
Focus Adverse reactions

Most Recent Events

16 Dec 2010 Results are expected to be presented at the 15th International Congress of Parkinson's Disease and Movement Disorders, according to a Manhattan Pharmaceuticals media release.
16 Dec 2010 Primary endpoint 'Clinical-response' has not been met, according to a Manhattan Pharmaceuticals media release.
16 Dec 2010 Interim results reported in a Manhattan Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com